The immune organoid was created in the lab of Ankur Singh, assistant professor of mechanical and aerospace engineering, who applies engineering principles to the study and manipulation of the human immune system. The work was published online June 3 in Biomaterials and will appear later in print.
The synthetic organ is bio-inspired by secondary immune organs like the lymph node or spleen. It is made from gelatin-based biomaterials reinforced with nanoparticles and seeded with cells, and it mimics the anatomical microenvironment of lymphoid tissue. Like a real organ, the organoid converts B cells – which make antibodies that respond to infectious invaders – into germinal centers, which are clusters of B cells that activate, mature and mutate their antibody genes when the body is under attack. Germinal centers are a sign of infection and are not present in healthy immune organs.
The engineers have demonstrated how they can control this immune response in the organ and tune how quickly the B cells proliferate, get activated and change their antibody types. According to their paper, their 3-D organ outperforms existing 2-D cultures and can produce activated B cells up to 100 times faster.
The immune organ, made of a hydrogel, is a soft, nanocomposite biomaterial. The engineers reinforced the material with silicate nanoparticles to keep the structure from melting at the physiologically relevant temperature of 98.6 degrees.
The organ could lead to increased understanding of B cell functions, an area of study that typically relies on animal models to observe how the cells develop and mature.
What’s more, Singh said, the organ could be used to study specific infections and how the body produces antibodies to fight those infections – from Ebola to HIV.
“You can use our system to force the production of immunotherapeutics at much faster rates,” he said. Such a system also could be used to test toxic chemicals and environmental factors that contribute to infections or organ malfunctions.
The Latest on: Immune therapies
via Google News
The Latest on: Immune therapies
- Noile-Immune Biotech and C4U team up to develop CRISPR/Cas3 technologyon June 26, 2020 at 11:36 pm
Noile-Immune Biotech Inc., ("Noile-Immune") and C4U Corporation, ("C4U") announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic ...
- What is the treatment for COVID-19 patients? Montgomery doctor explainson June 26, 2020 at 8:12 pm
Most people who get diagnosed with COVID-19 will be able to recover at home. But what is it like for those that end up in the hospital?
- How the Coronavirus Short-Circuits the Immune Systemon June 26, 2020 at 6:03 pm
In a disturbing parallel to H.I.V., the coronavirus can cause a depletion of important immune cells, recent studies found.
- Sex dependent effects of post-natal penicillin on brain, behavior and immune regulation are prevented by concurrent probiotic treatmenton June 25, 2020 at 2:13 am
There is increasing awareness of the need to consider potential long-term effects of antibiotics on the health of children. In addition to being associated with immune and metabolic diseases, there is ...
- ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatmenton June 24, 2020 at 11:28 am
ChemoCentryx, Inc., (CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to initiate clinical development in the first half of 2021. Data to be ...
- Cancer Immune Therapies Linked to Severe Covid-19 in Studyon June 24, 2020 at 9:45 am
The findings suggest that while immune therapies known as checkpoint inhibitors -- a class that includes Merck & Co.’s blockbuster Keytruda and Bristol-Myers Squibb Co.’s Opdivo -- may increase the ...
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulinon June 23, 2020 at 5:00 am
The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model Triple I/O Combination to Be Administered to ...
- COVID-19 Clinical Trial of Immune Therapy Open at Mount Sinai, Made Possible by Philanthropic Donationon June 18, 2020 at 10:59 am
Mount Sinai Health System is beginning the first clinical trial in the New York metropolitan region of an immune-boosting therapy in COVID-19 patients.
- Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder canceron June 17, 2020 at 11:05 am
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with ...
- UCSF, St. Jude Identify Key Culprit Driving Treatment Resistance in Deadly Immune Disorderon June 16, 2020 at 4:27 pm
The finding could offer additional insights into other immune conditions, including a type of childhood leukemia and the severe inflammation response in some children with COVID-19.
via Bing News